Drug Trial Radar · NCT07285005
A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
May 13, 2026
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Kaken PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, double-blind, randomized, placebo-controlled, parallel group, adaptive, multicenter study planned to be conducted at multiple sites in North America, Canada, Taiwan and South Korea. The purpose of this study is to measure the efficacy and safety of KP-001 compared with placebo in patients aged ≥2 years with common VM, common LM, or KTS/CLOVES syndrome. An independent data monitoring committee (DMC) will be established to determine whether to discontinue or continue the study. It will also determine the redesign of the number of cases based on the result of the interim analysis. The study will comprise the following: * Screening Period: Up to 42 days prior to the first dose of study intervention. * Treatment Period 1: This is a double-blind period in which KP-001 100 mg (or lower dose depending on their body weight) or placebo will be administered to patients once daily after breakfast until Week 24. * Treatment Period 2: After 24 weeks of double blind treatment, all patients will switch to the KP-001 open label extension and treated up to Week 52. * Follow-up Visit: This visit will occur 30 days after the last dose of study intervention, and assessments will be performed per the SoA. * Discontinuation Visit: Patients who discontinue study intervention will be requested to continue participating in the study and assessments will be performed per the SoA. If the patients request to withdraw from the study, all tests and evaluations when possible will be performed at Discontinuation visit.
Conditions
- Venous Malformations
- Lymphatic Malformations
- Klippel-Trenaunay Syndrome
- CLOVES Syndrome
Interventions
KP-001Drug
Oral repeated dose 100mg or lower
PlaceboDrug
Oral repeated dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- The ratio of volume of target lesions based on MRITime frame: pre-does and at 24weeks post-dose
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
University of Missouri - Columbia, School of Medicine
Columbia, Missouri · Recruiting
UNC Health Care - North Carolina Children's Hospital
Chapel Hill, North Carolina · Recruiting
MUSC Children's Health Primary Care
Charleston, South Carolina · Recruiting
St. Jude Children's Research Hospital
Memphis, Tennessee · Recruiting
Texas Children's Hospital
Houston, Texas · Recruiting
West Virginia University
Morgantown, West Virginia · Recruiting
Kyungpook National University Hospital - Pediatric
Daegu, Daegu, South Korea · Recruiting
Seoul National University Hospital
Seoul, Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, Seoul, South Korea · Recruiting
National Taiwan University Hospital - HsinChu Branch
Hsinchu, Hsinchu, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.